Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $6.1600 (1.99%) ($6.1600 - $6.1600) on Tue. Jul. 20, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.17% (three month average) | RSI | 44 | Latest Price | $6.1600(1.99%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.7% a day on average for past five trading days. | Weekly Trend | AUTL declines -5.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(55%) ARKG(49%) ARKK(49%) IWO(48%) ACES(47%) | Factors Impacting AUTL price | AUTL will decline at least -3.085% in a week (0% probabilities). VIXM(-30%) VXX(-27%) SHY(-18%) TLT(-16%) XLU(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.085% (StdDev 6.17%) | Hourly BBV | 1.4 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-4.2(-168.18%) | Resistance Level | $6.56 | 5 Day Moving Average | $6.02(2.33%) | 10 Day Moving Average | $6.32(-2.53%) | 20 Day Moving Average | $6.56(-6.1%) | To recent high | -22.4% | To recent low | 23% | Market Cap | $322m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |